Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)

European Journal of Clinical Pharmacology

Volumn 55, Issue 4, 1999, Pages 279-283

  Sandwall, P ^a   Lo, M W ^b   Jonzon, B ^c   Dalen P ^c   Furtek, C ^b   Ritter, M ^b   Alvan G ^c   McCrea, J ^b   Sjoqvist F ^c  

^a Merck Sharp Dohme (Sweden)   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome P450; Losartan; Polymorphism

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450; DEBRISOQUINE; DRUG METABOLITE; LOSARTAN; MEPHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032937589     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050629     Document Type: Article

References (19)

1. 1. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251
2. 2. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641-649
3. 3. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR (1992) Drug concentration response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 51: 513-521
4. 4. Stearns RA, Chakravarty PK, Chen R, Chiu SHL (1995) Biotransformation of losartan to its active metabolite in human liver microsomes. Drug Metab Dispos 23: 207-215
5. 5. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, Lo MW, Goldberg M (1996) A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther, Ninety-seventh annual meeting of the American Society for Clinical Pharmacology and Therapeutics, February 1996 59: 215
6. 6. McCrea JB, Lo MW, Furtek CI, Ritter MA, Carides A, Waldman CA, Bjornsson TD, Goldberg MR (1996) Ketoconazole does not effect the systemic conversion of losartan to E-3174. Clin Pharmacol Ther, Ninety-seventh annual meeting of the American Society for Clinical Pharmacology and Therapeutics February 1996 59: 169
7. 7. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams Jr EJ, Bjornsson TD (1993) Effects of losartan on blood pressure, plasma renin activity and angiotensin II in volunteers. Hypertension 21: 704-713
8. 8. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-586
9. 9. Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionization and nitrogen-selective detection. J Chromatography 133: 161-166
10. 10. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102-105
11. 11. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish population in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51: 388-397
12. 12. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR (1984) Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatography 307: 121-127
13. 13. Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 45: 495-499
14. 14. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51: 12-17
15. 15. Skoda RC, Gonzalez FJ, Demierre A, Mayer UA (1988) Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240-5243
16. 16. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
17. 17. Ritter MA, Furtek CI, Lo MW (1997) An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 15: 1021-1029
18. 18. Lam FC, Hung CR and Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74: 229-231
19. 19. Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53: 445-449